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Abstract
Background: Multiple Myeloma (MM) is a hematological malignancy with genomic heterogeneity and poor
survival outcome. Apart from the central role of genetic lesions, epigenetic anomalies have been identified as
drivers in the development of the disease.
Methods: Alterations in the DNA methylome were mapped in 52 newly diagnosed MM (NDMM) patients of six
molecular subgroups and matched with loci-specific chromatin marks to define their impact on gene expression.
Differential DNA methylation analysis was performed using DMAP with a ≥10% increase (hypermethylation) or
decrease (hypomethylation) in NDMM subgroups, compared to control samples, considered significant for all the
subsequent analyses with p<0.05 after adjusting for a false discovery rate.
Results: We identified differentially methylated regions (DMRs) within the etiological cytogenetic subgroups of
myeloma, compared to control plasma cells. Using gene expression data we identified genes that are dysregulated
and correlate with DNA methylation levels, indicating a role for DNA methylation in their transcriptional control. We
demonstrated that 70% of DMRs in the MM epigenome were hypomethylated and overlapped with repressive
H3K27me3. In contrast, differentially expressed genes containing hypermethylated DMRs within the gene body or
hypomethylated DMRs at the promoters overlapped with H3K4me1, H3K4me3, or H3K36me3 marks. Additionally,
enrichment of BRD4 or MED1 at the H3K27ac enriched DMRs functioned as super-enhancers (SE), controlling the
overexpression of genes or gene-cassettes.
Conclusions: Therefore, this study presents the underlying epigenetic regulatory networks of gene expression
dysregulation in NDMM patients and identifies potential targets for future therapies.
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Introduction
Multiple Myeloma (MM) is characterized by an abnormal
clonal plasma cell infiltration in the bone marrow, which
may lead to the development of lytic bone lesions and mye-
losuppression [1, 2]. The etiological genetic features of MM
include translocations between the IgH locus and a number
of oncogenes, including MMSET/FGFR3 (4p16), CCND1
(11q13), MAF (16q23), MAFB (20q12), or aneuploidy dem-
onstrated in patients with hyperdiploid genomes [3–5]. In
addition to etiological events, secondary acquired genetic
abnormalities, including recurrent mutations, have been re-
ported. These acquired genetic abnormalities deregulate
key oncogenes and tumor suppressor genes in MM [6].
Few studies in myeloma have attempted to clarify the epi-
genetic drivers and their impact on the underlying disease,
with the majority having focused on global alterations in
DNA methylation, histone modifications, and noncoding
miRNAs [7–11]. Individual epigenetic marks have been in-
vestigated through the use of low-throughput techniques,
such as methylation specific PCR, pyrosequencing, and
semi-high output 450K methylation arrays [8, 9, 12].
Regarding DNA methylation, we and others have shown
that there is a significant change in DNA methylation levels
at the transition from monoclonal gammopathy of undeter-
mined significance (MGUS) to MM, resulting in genome-
wide hypomethylation while specific genes are hypermethy-
lated [8, 11]. There is also a clear difference in the DNA
methylation levels in the t(4;14) MM subgroup compared to
other subgroups, and this is thought to be due to over-
expression of the histone methyltransferase MMSET in this
group. DNA methylation has also been used to identify genes
of prognostic interest, highlighting the importance of this bio-
logical process [9]. However, the possible internal cross-talk
between epigenetic regulators at the DNA and histone levels
and their combinatorial effects on gene expression patterns in
different MMmolecular subgroups has not been addressed.
To address this deficiency, we have optimized the use
of enhanced reduced representation bisulfite sequencing
(eRRBS), complemented with 850K methylation array
(Illumina), in newly diagnosed MM (NDMM) patients of
six molecular subgroups to determine the alterations in
DNA methylome per subgroup in order to compare to
healthy donors. Enrichment of promoter and gene body-
associated CpG sites allows robust correlation between
DNA methylation at differentially methylated regions
(DMRs) and expression of the closest gene. Additionally,
we show that these DMRs co-localize with other epigen-
etic factors, including histone marks and SE protein sig-
natures, to impact gene expression dysfunction in MM.
Methods
Patients and sample preparation
Fifty two NDMM patients were consented with IRB ap-
proval for bone marrow aspirates for CD138+ cell selection
(RoboSep, StemCell Technologies, Germany) to enrich
for tumor cells at least >90%. Patients represented the
major translocation and hyperdiploidy subgroups and
were compared to CD138+ PCs isolated from bone-
marrow random aspirates of four age-matched healthy
donors. These patients were well-characterized in
terms of diagnostic variables, demographic, and clini-
copathological parameters (Supplementary Table 1).
DNA and RNA were extracted using AllPrep DNA/
RNA mini kit (Qiagen, Hilden, Germany), RNeasy
RNA extraction kit (Qiagen), or Puregene DNA ex-
traction kit (Qiagen). Bisulfite conversion of DNA was
carried out using EZ-DNA methylation kit (Zymo Re-
search, CA, USA).
eRRBS sample processing, library preparation, and
sequencing
The eRRBS protocol was optimized with 100 ng of gen-
omic DNA. Briefly, DNA samples were digested over-
night with MspI followed by end-repair and A-tailing,
methylated adapter ligation, uracil removal treatment,
magnetic bead-based size selection, bisulfite conversion,
and PCR enrichment [13]. The size and concentration of
library fractions were determined prior to sequencing.
Samples were multiplexed and sequenced using 75-bp
single end reads.
Interpretation of eRRBS data
Quality control of the sequencing reads and methyla-
tion base calling were performed using bcl2fastq2
(Illumina) and TrimGalore (v 0.4.4) software, respect-
ively. We obtained an average of 2.198x107 total
aligned reads per sample and measured the methyla-
tion levels of an average of 21 million methylated
CpG sites per sample from the eRRBS data (Supple-
mentary Table 1). Sequencing data were aligned to
whole genome version hg38/GRCh38 using the Bis-
mark alignment software (v 13.0) (Babraham Bioinfor-
matics, UK). Differential methylation analysis was
performed using DMAP (v 1.42) [14] and cytosines
with fewer than 10 reads in any sample were
discarded from subsequent analyses. Bismark quality
control report on the eRRBS data are listed in
Supplementary Table 2.
DMRs containing at least 2 CpG sites were considered
for subsequent analyses, provided the methylation per-
centage of both the control and NDMM groups were
not >80%, <20%, or between 40% and 60%. DMRs of
≥10% (a false discovery rate [FDR]-adjusted p-value <
0.05) increase (hypermethylation) or decrease (hypome-
thylation) in NDMM subgroups, compared to control
samples, were considered significant for all the subse-
quent analyses. DMRs were annotated by identifying the
closest TSS according to RefSeq. Regions that were 5 kb
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upstream and 200 bp downstream from the TSS were
marked as promoter regions, while the region immedi-
ately downstream of the defined promoters to the 3’
ends were marked as gene body. Relative distance per-
centage (D) of a DMR from the nearest TSS site was cal-
culated using the following formula:
D= (Absolute distance from the end base of DMR-TSS
start base/Gene length) X 100
Genes with the combination of both hyper- and hypo-
methylated DMRs at promoter or body are excluded
from the present study. An unsupervised hierarchical
clustering was performed using the top 5% most variable
CpG sites using hclust method in R.
MethylationEPIC 850k bead array
Methylation array was performed in 48 patients, includ-
ing 34 of the 52 NDMM patients of the eRRBS dataset
in addition to 14 NDMM samples. 500 ng of genomic
DNA was used as input. Genomic DNA were bisulfite
converted and processed on Infinium HumanMethyla-
tionEPIC BeadChip arrays (Illumina Inc., CA, USA) per
manufacturer’s protocol. Microarray raw IDAT and an-
notation files (Infinium MethylationEPIC v1.0_B4 Mani-
fest File) for the EPIC assay were loaded into
GenomeStudio software (v 1.9.0, Illumina) for differen-
tial methylation analysis. Difference in the average
methylation proportion (β value) at a CpG site between
control and NDMM patients >0.1 were considered sig-
nificant at a diffscore >+/-13 (equivalent to adjusted p-
value 0.05). All downstream analyses were conducted by
converting the hg19/GRCh37 coordinates of EPIC
probe-sets (default in GenomeStudio) to hg38/GRCh38
using the UCSC lift-over tool to match and validate the
eRRBS data, wherever possible.
Gene expression profiling
Gene expression profiling (GEP) using Affymetrix U133
Plus 2.0 arrays was performed. CEL files were processed
using the Transcriptome Analysis Console (v 4.0,
Thermo Fisher, CA, USA), where raw intensity values
were MAS5 normalized and converted to log2 scale.
Average GEP value over 2-fold more or less in NDMM
patients compared to controls were defined as overex-
pressed and under-expressed genes respectively.
RNA sequencing
RNA sequencing was performed on 45 out of the 52
NDMM patients (as specified in Supplementary Table
1). RNA-seq was performed using 100 ng total RNA
with genomic DNA removal using the TURBO DNA-
free kit (Ambion). RNA was prepared using the TruSeq
stranded total RNA Ribo-zero gold kit (Illumina) and li-
braries were sequenced using 75 bp paired end reads on
a NextSeq500 (Illumina). RNA-seq data was analyzed
using the transcript aligner STAR (v2.5.1b) [15] and
transcript level data were generated by Salmon (v0.7.2)
[16]. RNA-sequencing and microarray data were com-
pared for key genes per NDMM subgroup (Supplemen-
tary Figure 11).
Intersect analysis of methylation and expression
A Venn intersection analysis was carried out using
Venny (v 2.0) to identify the hypermethylated under-
expressed and hypomethylated overexpressed genes at
the promoter. Additionally, the methylation and expres-
sion correlations were determined on hypomethylated-
under-expressed and hypermethylated-overexpressed
gene clusters at the gene bodies.
Gene ontology and protein interaction prediction
Gene clusters per MM subgroup and their possible in-
volvement in biological processes and molecular func-
tions were determined using the GO enrichment
analysis platform (http://geneontology.org/page/go-en-
richment-analysis) at FDR <0.05. Possible functional
protein interactions and involvement in KEGG anno-
tated pathways of the gene clusters were further ana-
lyzed with STRING consortium (https://string-db.org/
cgi/network.pl) tools (v 10.5).
Histone modifications (ChIP-seq) analysis
Chromatin immunoprecipitation and fixation were car-
ried out per manufacturer’s protocol (Active Motif Inc.)
on mycoplasma free and STR (short tandem repeat)
checked KMS11 and MM1.S cells. Antibodies were used
to determine genome-wide four activating histone
marks, namely H3K4me3, H3K27ac, H3K4me1, and
H3K36me3, and two inactivating histone marks, namely
H3K9me3 and H3K27me3 and data are available under
accession number GSE151556. Purchase of ChIP anti-
bodies, experiments, and analyses of the data were car-
ried out in association with Active Motif Inc. (CA, USA).
The histone marks for the U266 cell line were obtained
from the Blueprint epigenome consortium (http://www.
blueprint-epigenome.eu/). MACS2 was used for peak
calling to determine the enrichment of histone marks
both at the short and larger overlapping DMRs [17]. De-
lineation of significantly ChIP-enriched regions were
made in the form of SICER BED files and [18] were
uploaded in UCSC custom track to align histone marks
to the DNA and SE-CTCF modifications.
Annotations for CTCF, super-enhancer, and enhancer sites
Possible overlap of CTCF sites with the DMRs were de-
termined by using ChIP-seq data for CTCF in the
delta47 myeloma cell line [19]. Possible overlaps of SE
with DMRs were determined by using ChIP-seq data
from Lovén et al. 2013, from BRD4 binding in the
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MM1.S [20] cell line. The clustering of the SE/CTCF-
DMRs were performed by determining the average link-
age of DMR-methylation level using Euclidian distance
method.
Statistical analysis
A two-way ANOVA was used to determine the signifi-
cance in differential methylation analysis. A non-
parametric two tailed Mann-Whitney U test was per-
formed for rest of the analysis and statistical analyses
were determined at a p value < 0.001 or < 0.05 (as
indicated).
Results
Differential DNA Methylation Patterns Define NDMM
Molecular Subgroups
Using eRRBS, an unbiased genome-wide DNA methyla-
tion analysis of sorted CD138+ bone marrow (>98%
enriched for tumor) plasma cells (PCs) from 52 NDMM
patients was performed (Supplementary Table 1). Our
sample set contained four of the major IgH etiologic
translocation MM subgroups, including t(4;14), t(11;14),
t(14;16), and t(14;20) and two hyperdiploid (HRD) MM
subgroups, defined by overexpression of CCND1 (HRD-
D1) or CCND2 (HRD-D2) (Supplementary Table 2).
Principle-component analysis (PCA) of CpG methyla-
tion at DMRs showed a distinct segregation pattern of
t(4;14) samples from the control PCs and remaining sub-
groups (Supplementary Figure 1). The top 5% most
variable DMRs (n=12,926 unique regions) among the
MM subgroups were used to determine the level of
methylation across the corresponding gene bodies, pro-
moters, or intergenic regions (IGR) (Supplementary
Table 3). The majority of these most variable DMRs
were observed within the body (51%), followed by IGRs
(39%), and promoters (10%) (Fig. 1a, Supplementary
Figure 2A) with all regions and subgroups showing sig-
nificant hypomethylation compared to the control. An
unsupervised hierarchical clustering of DMRs (p<0.001)
across the MM subgroups demonstrated relative hyper-
methylation (19.6%) in the t(4;14) subgroup (Fig. 1b). In
contrast, the average number of hypermethylated DMRs
were as low as 5.6% in HRD, 4.3% in maf subgroups, and
3.4% in the t(11;14) subgroup. Based on the similarities
in DMRs, we also observed close neighboring clusters
between the t(14;16) and t(14;20), or between the HRD-
D1 and HRD-D2 subgroups. In contrast, the t(4;14) sub-
group was distant from all other subgroups, presumably
due to the over-expression of MMSET resulting in
changes in histone and DNA methylation (Supplemen-
tary Figure 2B).
The data obtained from eRRBS were complemented
with 850K methylation microarray data to demonstrate
differential methylation within and beyond the DMRs.
We again used the top 5% most variable differentially
methylated cytosines (DMCs) and clustered them to de-
termine subgroup methylation disparities. We observed
correlations between the methylation pattern of the
most variable DMRs and DMCs across the subgroups,
r2=0.91. Genomic distribution of the DMCs among the
subgroups are tabulated in Supplementary Table 4.
Based on the PCA and methylation pattern at DMCs, we
found similar neighboring DMC-clusters between the
t(14;16) and t(14;20), or HRD-D1 and HRD-D2 sub-
groups, Supplementary Figures 3 and 4. Moreover, the
t(4;14) was again most distantly separated from the other
MM subgroups.
The Expression Pattern Typical of Molecular Subgroups
Are Associated with DNA Methylation
We analyzed gene expression profiles in the same 52
NDMM patients to understand the subgroup-specific
differences in transcriptome profile and their possible
correlation with the altered methylation (Supplemen-
tary Figure 5A-F). Based on clustering analysis of the
top 5% most variably expressed genes the t(14;16) and
t(14;20) subgroups clustered together, as did the HRD-
D1 and HRD-D2 subgroups, while the t(4;14) and t(11;
14) subgroups remained isolated from all other sub-
groups (Supplementary Figure 5G), mirroring the
DNA methylation clusters.
The hierarchical clustering of DMR/DMC data
therefore resulted in a very similar clustering of the
expression data, suggesting expression and methyla-
tion patterns in NDMM subgroups may be intercon-
nected. We therefore carried out an unbiased
intersection analysis containing median methylation
level of DMRs versus nearest gene expression per
subgroup. In consensus with the literature, we fo-
cused on the promoters, where DMRs are inversely
correlated with expression, and at the gene body,
where DMR-methylation is positively correlated with
corresponding gene-expression [21, 22], defining them
as genes whose expression correlates with DNA
methylation (GEMs). Differential gene-expression of
≥2-fold between NDMM patients and control were
matched to the DMRs or the corresponding genes,
where differential methylation between NDMM pa-
tients and control were ≥10%. We observed that of
the genes differentially expressed in each subgroup,
GEMs accounted for 36.1% in t(4;14), 39.7% in t(11;
14), 42.4% in t(14;16), 47.1% in t(14;20), 45.5% in
HRD-D1, and 44.2% in the HRD-D2 subgroup. It was
also observed that number of over-expressed GEMs
per subgroup were almost two-times (Supplementary
Table 5) more than the under-expressed ones.
Furthermore, we compared the DMR-density distribu-
tion at the promoter and body of the GEMs across the
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subgroups to have a better understanding of the regional
effect of DNA methylation on gene expression. Based on
the significance of probability (Pr>F), we showed that
the hypomethylated but not the hypermethylated DMRs
had a significantly different distribution (Supplementary
Figure 6) at both the promoter and gene body across
the subgroups, and that this difference is mostly due to
the t(4;14) subgroup. It was also observed that the t(4;
14) GEMs had the lowest number of DMRs, while the
t(11;14) and t(14;20) GEMs had the highest number of
DMRs, compared to the control. Overall, on average we
found >42% of differentially expressed genes in MM are
controlled by DNA methylation. We also observed that
DNA methylation at the DMRs or DMCs at the gene
body were directly proportional to gene expression
levels, with a correlation of at least r2=0.58 across the
subgroups.
Histone Modifications Are Tightly Linked to the
Overlapping DMRs and DMCs
We also assessed the global overlap in activating
(H3K4me1, H3K4me3, H3K27ac, and H3K36me3) or re-
pressive (H3K9me3 and H3K27me3) histone marks with
DMRs for a better understanding of the underlying epi-
genetic networks of gene expression in NDMM [23, 24].
We analyzed the DMR-histone overlap (>50 bp) in the
t(4;14) MM subgroup using data from KMS11 cell lines,
in the t(11;14) with U266 cells and in the t(14;16) with
MM1.S cells.
Fig. 1 DNA methylation differs by myeloma subgroup. (a) The median DNA methylation level of the top 5% differentially methylated regions
(DMRs) of MM subgroups, compared to control (p<0.001), depicted as boxplots with interquartile range between 25% and 75% across the
promoters (n=1,282), gene body (n=6,594) and intergenic regions (n=5,050). (b) Unsupervised hierarchical clustering with the top 5% most
variable DMRs (n=12,931) showed distinct methylation pattern among the NDMM subgroups.
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We found H3K27me3 as the most abundant mark on
hypomethylated DMRs at both the promoter and gene
body in t(4;14), t(11;14) and t(14;16) subgroups (Supple-
mentary Table 19). We also observed enrichment of
H3K4me3 next to H3K27me3 at the hypomethylated
DMRs in promoters.
In contrast, hypermethylated DMRs were predominantly
enriched with H3K4me1, H3K4me3, or H3K36me3 at
both the promoters and bodies in the representative cell
lines. Most interestingly, these gene-body DMRs were pri-
marily correlated to overexpression of the related GEMs
(Supplementary Fig 7A-C). This finding supports the hy-
pothesis that similar to other cancers, DNA methylation
within the gene body may also play an important role in
determining expression in MM [25, 26]. A relatively low
amount of H3K27ac was also observed at the promoters
or gene-bodies but that relate to at least 14% overexpres-
sion in KMS11 t(4;14), 12% in U266 t(11;14), and 15% in
MM1.S t(14;16) subgroups. A low fraction of H3K9me3
was also noticed, which did not necessarily correlate to
any significant number of gene suppression.
Finally, a bimodal distribution in DMR-histone over-
laps were observed at the IGRs in all the cell types. For
instance, 80% hypomethylated DMRs in KMS11, 54% in
U266, and 67% in MM1.S cells were overlapped to
H3K27me3. In contrast, enrichment of H3K4me3 to
hypermethylated DMRs in the cell lines suggest the ex-
istence of potential distal cis-regulatory control of gene-
expression at the IGRs in MM [27]. In summary, DNA
methylation and histones in NDMM are tightly linked to
each other and involved in diverse array of epigenetic re-
lationships impacting gene expression.
Epigenetic Transcriptional Regulatory Networks in the
t(4;14) Subgroup
A pairwise comparison in median DMR-methylation
(MDM) between control and the t(4;14) subgroup re-
vealed 538 DMRs at promoters and 3798 DMRs within
the gene body. Of these DMRs, 671 correlated to the ex-
pression of their nearest gene (Fig. 2a and b; Supplemen-
tary Table 7). Of the total, we also identified 18 (3.4%)
GEMs, reported previously in relation to their oncogenic
importance in MM (Supplementary Table 6). We identi-
fied key t(4;14)-associated genes out of 257 GEMs includ-
ing C1orf21, CST3, DSG2, JAM3, LARP6, LRP12, MPPE
D2, MYRIP, or NRIP1, in which the median hypermethyla-
tion at the gene-body DMRs was correlated to their over-
expression. Also, 305 GEMs, including SYK, contained
hypomethylated gene body DMRs and were found to be
under-expressed [28]. Heat-maps containing DMR-
methylation and expression of corresponding genes, based
on the correlation coefficient (r2>0.2) across the MM sub-
groups, were plotted (Fig. 2c).
Next, we demonstrated the epigenetic impact on the
expression of two chosen t(4;14) GEMs, DSG2 and
TEAD1 [3, 29]. Three hypermethylated DMRs at the
DSG2 promoter, where the MDM changed from 27% in
the control to 39% in the t(4;14) group (p<0.05),
enriched with H3K4me1, H3K27ac, and H3K4me3 acti-
vating marks were identified. In contrast, five
Fig. 2 Methylation-expression correlation in the t(4;14) and t(11;14) subgroups. DNA methylation level (horizontal; median values) at DMRs vs.
expression (vertical; log2 values) of nearest genes were plotted for promoter (a) and gene body (b) in t(4;14) and t(11;14) (d, e) subgroups
compared to the control. DMR methylation level vs. expression (based on correlation r2>0.2, excluding control) of selected biologically relevant
GEMs in MM were represented as heat maps for the t(4;14) (c) and t(11;14) subgroup (f).
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hypermethylated DMRs at the gene body, with an MDM
change from 34% in the control to 45% in t(4;14) (p<
0.05) samples, were enriched with H3K36me3 (Fig. 3a
and b). In contrast, TEAD1 contained 16 hypomethy-
lated DMRs, where the MDM changed from 14% in con-
trol to 1.4 % in t(4;14) (p<0.05) samples at the promoter
and 31 hypermethylated DMRs, where the MDM chan-
ged from 54% in control to 68% in t(4;14) (p<0.05) sam-
ples at the gene body (Fig. 3c). TEAD1 gene body DMRs
overlapped with several activating histone marks (Fig.
3d). Differential expression of DSG2 in t(4;14) is thus
epigenetically supported by gene body hypermethylation
and enrichment in H3K36me3, while TEAD1 expression
was related to the canonical DNA methylation-
expression relationship at the promoter and gene-body.
Finally, we predicted the involvement of the t(4;14)
GEMs in KEGG annotated pathways (Supplementary
Table 8). GEMs with increased expression due to pro-
moter hypomethylation were associated with spliceo-
some assembly or oxidative phosphorylation pathways,
while upregulated GEMs with hypermethylation at the
gene body were associated with mTOR, Rap1, PI3k-AKt,
or MAPK pathways (Supplementary Table 8).
Epigenetic Transcriptional Regulatory Networks in the
t(11;14) Subgroup
We identified 7510 DMRs and 949 GEMs (Supplementary
Table 9), including 18 genes (1.8%) that were previously re-
ported as key oncogenes in the t(11;14) subgroup
(Supplementary Table 6). For example, CCND1, FAM84B,
MKX, PDZRN4, SHISA2, and XPOT contain hypomethy-
lated DMRs at the promoters and were over-expressed;
while, CCND2, NFIB, and RFTN1 contain hypomethylated
DMRs at the gene body and were under-expressed (Fig. 2d
and e) . We further narrowed down to 5 GEMs including
PDZRN4, CCND2, NFIB, RFTN1, and SORT1 based on the
level of methylation-expression correlation (r2>0.2) (Fig. 2f).
The epigenetic alterations on RFTN1 and SORT1 ex-
pression were investigated in the subgroup [30]. We
did not observe any significant difference in methyla-
tion across five DMRs at the RFTN1 promoter. How-
ever, the majority of the gene body DMRs were
hypomethylated in t(11;14) (MDM: 19%), compared to
controls (MDM: 69%) (Figs. 2f and 4a). We also ob-
served H3K27me3 repressive marks across the gene
body (Fig. 4b) using U266 cell line data. This two-
tier combinatorial epigenetic effect is correlated to
under-expression of the gene. In contrast, SORT1 was
overexpressed and contained hypermethylated DMRs
(MDM changed by 4% from control) across the gene
body (Fig. 4c) and overlapped with activating histone
marks (Fig. 4d).
Overexpressed t(11;14) GEMs containing hypomethy-
lated promoters or hypermethylated body are involve-
ment in MAPK signaling, focal adhesion, oxidative
phosphorylation, microRNA metabolism, or cancer re-
lated cell cycle pathways. In contrast, under-expressed
GEMs were predicted to be involved in cell adhesion
Fig. 3 DNA methylation and histone modification profile of DSG2 and TEAD1 in the t(4;14) subgroup. (a) DNA methylation distribution along the
DMRs (p<0.05) at the promoter (up to 5 kb upstream of the TSS) and gene body of the DSG2 transcript ENST00000261590.12. (b) Observed
enrichment of activating histone marks, such as H3K4me1, H3K4me3 or H3K27ac at the promoter and H3K36me3 at the gene body of DSG2 in a
t(4;14) cell line. (c) DNA methylation distribution along the DMRs (p<0.05) of the TEAD1 transcript ENST00000527575.5. (d) Observed enrichment
of activating histones as the major marks, overlapped with TEAD1 DMRs.
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molecules, JAK-STAT signaling, or calcium signaling
pathways (Supplementary Tables 10).
Epigenetic Transcriptional Regulatory Networks In maf
Subgroups
In the maf subgroups, t(14;16) and t(14;20), we identified
517 mutually shared GEMs, including 28 genes, which are
specifically overexpressed in this subgroup
(Supplementary Table 11 and 12). For example, we ob-
served a negative correlation of MDM at the promoters
with increased expression of 208 GEMs in t(14;16) and
251 GEMs in t(14;20) subgroups. These GEMs included
previously known oncogenes such as ARHGAP6, AHNAK,
ARID5A, GULP1, NUAK1, and PRR15 (Figure 5a and c)
in the maf subgroups. Additionally, BASP1 and SYNGR1
were identified among the hypomethylated and under-
Fig. 4 DNA methylation and histone modification profile of RFTN1 and SORT1 in the t(11;14) subgroup. (a) DNA methylation distribution along
the DMRs (p<0.05) at the promoter (up to 5 kb upstream to the TSS) and gene body of the RFTN1 transcript ENST00000334133.8. (b) Observed
enrichment of repressive H3K27me3, overlapped with hypomethylated DMRs at the gene-body. (c) DNA methylation distribution along the DMRs
(p<0.05) of the SORT1 transcript ENST00000256637.7. (d) Observed enrichment of activating histones such as the H3K36me3, overlapped with
SORT1 hypermethylated DMRs at the gene body. Histone marks were obtained from a t(11;14) cell line.
Fig. 5 Methylation-expression correlation in the t(14;16) and t(14;20) subgroups. DNA-methylation level (horizontal; median values) at DMRs vs.
expression (vertical; log2 values) of nearest genes were plotted for promoter (a) and gene body (b) in t(14;16) and t(14;20) (c, d) subgroup.
Median DMR methylation level vs. expression (based on correlation r2>0.2, excluding control) of selected biologically relevant GEMs in t(14;16) (E)
and t(14;20) (F) subgroups.
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expressed genes [n=404 in t(14;16) and n=504 in t(14;20)],
and MTSS1 among the hypermethylated-overexpressed
GEMs [n=385 in t(14;16) and n=427 in t(14;20)] (Fig. 5b
and d). We also observed t(14;16)-specific GEMs, such as
PRR15 and SFN, or t(14;20)-specific GEMs, such as
CDKN1C, at the promoter.
Next, we focused on fifteen mutually shared GEMs, of
which expression of 8 genes corresponded to the MDM
at the promoter, while the remaining GEMs were corre-
lated with the MDM at the gene body (Fig. 5e-f; Sup-
plementary Table 6). Additionally, we examined the
DNA methylation and histone level changes in two key
GEMs in the maf subgroups [3, 31], namely NUAK1 and
LCP2. NUAK1 was over-expressed and contained two
hypomethylated DMRs [MDM reduced to 22% in t(14;16);
21% in t(14;20), compared to control (MDM: 25%; p<
0.05)] at the promoter. The gene contained relatively
hypermethylated DMRs at the gene body (Fig. 6a), where
the MDM increased by 13% in t(14;16) and 5% in t(14;20),
compared to control (MDM: 43%; p<0.05). Enrichment of
the H3K36me3 throughout the gene body and H3K4me1,
H3K27ac, and H3K4me3 marks at the promoter of
NUAK1 were also observed (Fig. 6b). In contrast, LCP2
was over-expressed [4.6-fold in t(14;16) and 4.8-fold in
t(14;20) subgroup; p<0.05] probably due to the presence
of hypermethylated DMRs [MDM changed by 9% in t(14;
16) and 7% in t(14;20) respectively, compared to the con-
trol (MDM: 32%)(p<0.05)] (Fig. 6c) and enrichment of ac-
tivating histone marks across the gene body (Fig. 6d).
Finally, the hypomethylated-overexpressed GEMs at
the promoters in t(14;16) were predicted to be involved
in ribosome biogenesis pathway, while hypomethylated-
under-expressed GEMs at the body in the Rap1 signaling
pathway, or neuroactive ligand-receptor interactions
(Supplementary Table 13). The t(14;20)-specific hypo-
methylated- under-expressed GEMs at the body were
predicted to be involved in Rap1, sphingnolipid metabol-
ism, and galactose metabolism (Supplementary Table
14) pathways. Additionally, we identified involvement of
maf-GEMs in several common molecular functions such
as nuclear biosynthesis and regulation of cell cycle ma-
chinery (Supplementary Table 13 and 14).
Epigenetic Transcriptional Regulatory Networks In
Hyperdiploid Subgroups
We identified 5605 DMRs, corresponding to 777 GEMs
(Supplementary Table 15) in the HRD-D1 subgroup,
and 4672 DMRs in the HRD-D2 subgroup, corresponding
to 662 GEMs (Supplementary Table 16). We identified
n=55 (6.4%) GEMs amongst HRD-D1, but a relatively
small number of genes (n=3) for the HRD-D2 GEMs
(Supplementary Table 6) that have been reported in lit-
erature [30]. For instance, we identified some of the well-
known over-expressed genes of the HRD-D1 subgroup,
such as COL4A6, COX7C, ELL, ERCC1, MCC, NDUFS7,
and NOL4 among 228 genes containing hypomethylated
DMRs at the promoter (Fig. 7a). Similarly, of the known
over-expressed genes in HRD-D2 subgroup, we observed
Fig. 6 DNA methylation and histone modification profile of NUAK1 and LCP2 in the t(14;16) and t(14;20) subgroups. (a) DNA methylation
distribution along the DMRs (p<0.05) at the promoter (up to 5 kb upstream to the TSS) and gene body of the NUAK1 transcript
ENST00000261402.6. (b) Observed enrichment of activating H3K4me1, H3K4me3 or H3K27ac marks, overlapped with hypomethylated DMRs and
H3K36me3 marks overlapped with hypermethylated DMRs at the gene body of NUAK1 in a t(14;16) cell line. (c) DNA methylation distribution
along the DMRs (p<0.05) of the LCP2 transcript ENST00000392050.2. (d) Observed enrichment of several activating histones marks including
H3K36me3, H3K27ac, or H3K4me1, overlapped with hypermethylaated DMRs at the gene body.
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NOL4 and IL6R among the hypomethylated over-
expressed genes (n=194) at the promoter. CTSH, PKIG,
and TNFAIP2 appeared among the hypomethylated
under-expressed cluster (n=288), while TCFL5 appeared
among the hypermethylated over-expressed cluster (n=
209) at the gene body in HRD-D2 subgroup (Fig. 7b).
We predicted that over-expressed GEMs with hypome-
thylation at promoters in HRD-D1 were involved in ribo-
some biosynthesis, while suppressed GEMs containing
hypermethylation at the gene body were involved in PI3K-
Akt or Rap1 signaling pathways, cell adhesion molecule
regulation, or infection related responses (Supplementary
Table 17). The over-expressed GEMs containing hyper-
methylated bodies in the HRD-D2 subgroup were pre-
dicted to be involved in spliceosome assembly. In
contrast, hypomethylated under-expressed GEMs were in-
volved in Rap1 signaling, neuroactive ligand-receptor
interaction or similar to infection mediated responses
(Supplementary Table 18).
DNA Methylation Correlates with CCND2 Expression But
Not with CCND1 Expression.
We also examined the epigenetic regulation of CCND1
and CCND2, two key cell cycle regulators that are often
used to define the genomic subgroups of MM. CCND1
is highly expressed in the t(11;14) due to the proximity
of the translocated IGH SE and also in the HRD-D1 sub-
group due to gain of chromosome 11 (Fig. 8a). Con-
versely, the t(4;14), t(14;16), t(14;20), and HRD-D2 have
high expression of CCND2 (Fig. 8a) through an indirect,
ill-defined activation route.
Comparing these two cyclin genes we showed that ex-
pression is not correlated to DNA methylation for CCND1
(r2=0.14) but is highly correlated for CCND2 (r2=0.59,
Fig. 8b). For CCND1, as expected the t(11;14) have the
highest spike in expression but also have the lowest levels
of gene body methylation (Fig. 8b), which would normally
be associated with low expression levels. There was no
correlation between promoter or gene body methylation
and CCND1 expression (r2=0.066 and 0.0382, respect-
ively). However, the expression of CCND1 can be ex-
plained at the histone level, where the U266 cells with a
t(11;14) retain high levels of activating marks (H3K36me3,
H3K27ac, and H3K4me3) and do not have repressive
marks (H3K27me3 or H3K9me3), presumably due to the
presence of the translocated IGH locus SE, Fig. 8e.
For CCND2, there was a high correlation between
DNA methylation and expression both overall (r2=0.59)
and at the promoter and gene body (r2=-0.671 and
0.645, respectively). The t(11;14) and HRD-D1 sub-
groups, which have low CCND2 expression, had the
highest promoter methylation levels and the lowest gene
body methylation levels, which is consistent with low ex-
pression. The other subgroups, with high CCND2 ex-
pression, all had low or no methylation at the promoter
and high levels of gene body methylation, consistent
with high expression, Fig. 8c. In addition, in the CCND2
expressing cell lines KMS11 (Fig. 8g) and MM1.S (Fig.
8i) there was enrichment for active histone marks along
the promoter and gene body, which were not present
in the t(11;14) containing U266 cells (Fig. 8h). There-
fore, CCND2 expression is highly coordinated be-
tween DNA methylation and active histone marks,
which is not seen with CCND1. It has previously been
shown that CCND2 has a weak super-enhancer in
MM1.S cells [20] but the reason for the presence of
Fig. 7 Methylation-expression correlation the hyperdiploid subgroups. DNA-methylation level (horizontal; median values) at DMRs vs. expression
(vertical; log2 values) of nearest genes were plotted for promoter and gene body in HRD-D1 (a) and HRD-D2 (b) subgroups. DMR methylation
level vs. expression (based on correlation r2>0.2, excluding control) of selected biologically relevant MM GEMs were represented as heat maps for
HRD-D1 (c) and HRD-D2 subgroups (d).
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the super-enhancer is unclear. It may be that the
changes in DNA methylation are a result of the active
chromatin or vice versa.
The Functional Impact of CTCF and SEs at Overlapping
DMRs on Gene-overexpression.
Earlier literature suggest that altered DNA methylation
in the gene regulatory SE-elements may influence over-
expression of the target gene or gene-cassette by form-
ing a loop with the aid of CTCF TFs (Supplementary
Figure 8) [32]. With this in mind, we investigated the
potential overlap between the DMRs and SEs in con-
junction with CTCF binding sites in NDMM subgroups.
We identified 677 SE-DMRs, based on a ChIP-sequence
data for BRD4 in the MM1.S cell line [20], or 4,791
CTCF-DMRs from CTCF binding in the Delta47 cell
line [19], matched to the overlapping GEM-DMRs of the
NDMM patients. On average, we found 65% of SE and
82% of CTCF sites overlapped with hypomethylated
DMRs, while the remaining were overlapped with
hypermethylated DMRs (Supplementary Table 20).
Hierarchical clustering using the DMRs overlapping with
SE-CTCF sites generated three major SE-DMR or SE-
CTCF modules across the promoter, body, and IGRs.
These modules contained only differentially hypomethy-
lated, hypermethylated, or a combination of both (Sup-
plementary Figure 9) hyper/hypo-DMRs in the
subgroups compared to control.
Furthermore, we demonstrate the impact of SE-CTCF
loops at the H3K27ac enriched DMRs that regulate
overexpression of individual or cassettes of GEMs [3, 29]
in the t(14;16) subgroup. The promoter or gene-body of
these GEMs were either partially overlapped with the SE
elements or located within the overlapping SE-loops
[32]. We identified eighteen such hypomethylated and
over-expressed (>2 fold) GEMs in the t(14;16) subgroup
(Supplementary Table 20) to elaborate the combinator-
ial effect of DNA methylation, histone marks, and SEs
on gene expression. For example, TSS and promoter up-
stream regions of ARID5A and SMAD7 were located
Fig. 8 Distribution of DNA methylation and histone modifications of CCND1 and CCND2 in NDMM. (a) Median DMR methylation level vs.
expression correlated for CCND2 (r2=0.59), but not for CCND1 (r2=0.14) across the subgroups. DNA methylation levels across CCND1 (b) and
CCND2 (c) for each subgroup. (d) Chromatin marks at CCND1 (d) and CCND2 (E) in three different cells lines representing the t(4;14), t(11;14) and
t(14;16) subgroups.
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within a putative interstitial SE-loop, where the hypo-
methylated DMRs were overlapped with activating his-
tone marks, in particular H3K27ac (Fig. 9a and b). The
epigenomic architecture of these GEMs was associated
with a 5.7- and 4.4-fold increase in expression, respect-
ively, which was not seen in immediately adjacent genes,
outside of the SE-CTCF loops. We also observed the SE-
CTCF regulated over-expression of gene-cassettes. For
instance, we identified overexpression of LITAF, SNN,
TXNDC11, and ZC3H7A spanning over a 200 kb region
(Fig. 9c), as well as PLA2G15, SLC7A6, and PRMT7
spanning a 100 kb region (Fig. 9d) under the influence
of putative SE-loops. Moreover, MAF, the signature
oncogene of the t(14;16) subgroup, was 15.5 fold over-
expressed in our dataset while promoter and upstream
enhancer of MAF were partially overlapped to the SE el-
ements (Supplementary Figure 10), besides IgH-SE
overlap to the 3’-end of the gene (data not shown).
Discussion
In the present study, we have combined alterations in
genome-wide DNA methylation and histone modifica-
tions with regulatory mechanisms of SE-CTCFs to ex-
plain the subgroup-specific differential gene expression
dysfunctions in NDMM patients. The GEMs reported
here not only serve as the epigenetic biomarker for the
early detection of the disease, but also give an idea about
successive oncogenic transitions in MM.
Autosomal epigenetic traits in B cells are considered to
propagate to the daughter cells in an accumulative pattern
through the stages of differentiation [33] which
strengthens the importance of differential DNA methyla-
tion as a specific predictor of disease progression in MM.
We observed that the DNA methylation data points for
the top 5% variable DMRs were found to affect >94% of
autosomal CpG sites across the molecular subgroups. Fur-
thermore, we show that, except for t(4;14), DNA hypome-
thylation was prevalent across the major genomic regions
including promoters, gene bodies, or IGRs in the
remaining MM subgroups compared to age matched con-
trols. The amount of hypermethylation in t(4;14) relative
to non-t(4;14) subgroups may be explained by the over-
expression of MMSET, an H3K36 methyltransferase [34].
In contrast, global DNA-demethylation in MM subgroups
may be attributed to frequent mutations in epigenetic
modifiers, especially DNMT3A [35], which may create fa-
vorable conditions of genome-wide DNA hypomethyla-
tion within and outside the CpG islands.
When we combined methylation data at variable CpGs
with gene expression, it was found that even though
DNA-methylation is inversely correlated to the expression
in promoters of the nearest genes, they may be positively
correlated to the expression at the gene bodies, as evi-
denced by the key genes per subgroup. Moreover,
regulation of gene expression is not merely influenced by
the changes in DNA methylation at promoters or within
the gene body, but are tightly linked to the overlapping
chromatin modifications, or regulated from the juxtaposed
SE-CTCF loops (Supplementary Table 20). For instance,
we observed a series of GEMs, where the DMRs were dif-
ferentially hypomethylated at the gene body but remained
over-expressed in a particular MM subgroup. These
events could be correlated to the effect of the overlapping
activating histones or regulatory control from the SEs
(Supplementary Table 21). At the histone level, the ma-
jority of the hypomethylated DMRs overlapped with re-
pressive H3K27me3, while the majority of the
hypermethylated DMRs within the gene body overlapped
with H3K36me3 and H3K4me1 or H3K4me3 marks. A
strong association of these activating histones has already
been reported in relation to their regulatory role in the al-
ternative splicing mechanisms in cancer [36]. The prefer-
ential occurrence of these histones has also been reported
in MM as biomarkers and druggable targets [37–39]. Add-
itionally, loci-specific enrichment of H3K27ac at the
DMRs suggest the existence of interstitial SE-like regula-
tors, which may create a transcriptionally active state
resulting in over-expression of genes or gene clusters in
MM. We found that these acetylated and hypomethylated
DMR domains are also the preferential binding sites of
BRD4 or MED1. These BRD4/MED1 binding sites are
generally demarcated by CTCFs at the termini that pre-
sumably form the SE-CTCF loops. SE-CTCF loops span-
ning the length of an entire gene or gene-cassette lead to
the aberrant over-expression of genes.
The most common pathways predicted to be affected by
the GEMs of different MM subgroups, were PI3K/AKT/
mTOR, MAPK, Rap1 and the cell cycle. These pathways
align with the existing literature, where frequent activation
of the PI3K/AKT/mTOR pathway [40], or recurrent muta-
tions and aberrant expression of MAPK [41] or Rap1 [42]
genes have been reported in MM patients. Interestingly, six
GEMs in the t(4;14) subgroup were upregulated and are
part of the Rap-guanine nucleotide exchange family, up-
stream of Rap1. In contrast, a different set of GEMs in the
maf and HY subgroups, containing both upstream activa-
tors and downstream targets of Rap1 were down-regulated.
While the upstream regulators mainly constitute mem-
brane receptor kinases, the downstream GEMs were in-
volved in the cellular adhesion, polarity or migration
machinery. Cell-cycle pathway genes were also differentially
expressed, including CCND1, CCND2, and CDKN2C.
These genes are associated with proliferation and prognosis
in MM patients. Therefore, the present study provides dee-
per insights into the epigenetic control of gene expression,
and its involvement in different MM signaling pathways.
We also demonstrated epigenetically controlled expres-
sion of CCND1 and CCND2 among the MM subgroups.
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For instance, CCND1 is known to be overexpressed in the
t(11;14) subgroup and occurs through the juxtaposition of
the IgH-SE next to CCND1. This results in an epigenetic
sweep of the active histone marks from the IgH locus
across CCND1. In contrast, CCND2 is not expressed in
the t(11;14) subgroup, and may be explained by the en-
richment of repressive H3K27me3 marks, lack of activat-
ing H3K4me1 and H3K27ac marks, and hypomethylated
DMRs within the gene body of CCND2. In contrast, a
weak SE signal is present in the t(14;16) cell line MM1.S
at the CCND2 promoter, characterized by H3K27ac,
H3K4me3, and BRD4 enrichment. A similar ChIP profile
is seen in the t(4;14) cell line KMS11. These active histone
marks were found in conjunction with DNA hypermethy-
lation within the gene body of CCND2, indicating a pos-
sible interaction between the epigenetic states. An
interesting hypothesis would be to alter the DNA methyla-
tion levels within the body of CCND2 and determine if
this alters the chromatin marks and expression of the gene
in these high risk CCND2 expressing subgroups [43].
Conclusions
Overall, the present study highlights the existence and
impact of epigenetic regulatory networks in determining
expression abnormalities in the NDMM subgroups,
which play key roles in the onset and development of
the disease. We observed that under-expressed GEMs in
NDMM subgroups generally contained hypomethylated
DMRs enriched with repressive H3K27me3 marks; while
the overexpressed GEMs harbored clustered hypomethy-
lation at promoters and hypermethylation within the
gene body, interacting with activating histone marks.
Additionally, hypomethylated DMRs at the gene body or
promoters of certain GEMs were enriched with
H3K27ac and marked by the preferential binding of
BRD4 that behave as locally active elements. Previously,
Fig. 9 Super-enhancer control of gene-expression in MM. Overlapping of super-enhancer (SE)-CTCF loops to the hypomethylated DMRs of the
over-expressed (log2 scale) GEMs in t(14;16). (a) ARID5A is 5.74-fold overexpressed, while (b) SMAD7 is 4.44-fold over-expressed and are predicted
to be under control of a SE-CTCF loop. The surrounding genes do not show over-expression. (c) An over-expressed gene cassette containing LITA
F (2.94-fold increase), the GEM, SNN (5.6-fold increase), TXNDC11 (2.1-fold increase), and ZC3H7A (2.55-fold increase), spanning a 50 kb region or
(d) another gene cassette containing the GEM PLA2G15 (4.11-fold increase), SLC7A6 (4.28- fold increase), and PRMT7 (6.82-fold increase), spanning
over 20 kb region were identified in the t(14;16) subgroup. Red arrows show the putative boundaries of the SE-CTCF loops.
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the effect of recurrent mutations in epigenetic modifiers
in relation to the survival of MM patients was reported
by our group [35]. The data obtained here will give fur-
ther insight into the epigenetic mechanism of key genes
in MM, and also help in determining the subgroup-
specific therapeutic regimen. Currently DNA methyla-
tion modifying agents and bromodomain inhibitors such
as decitabine and JQ1 respectively, may be used to alter
the global aberrant epigenetic landscape of tumors and
regulate the abnormal expression of downstream
oncogenes.
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